Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Business & Technology Briefs (01/2007)

Executive Summary

A short summary of recent market and product developments in Interventional Cardiology, Spine Surgery, and Aesthetics, including: DES Safety Panel Weighs the Evidence; Percutaneous Lubar Fusion, and New Dermal Fillers.

You may also be interested in...



Can Stents Pull Off a Disappearing Act?

Just three years ago bioabsorbable stents seemed to be more of a "nice to have" than a "need to have." After all,drug-eluting stents (DES) were seen as the answer to restenosis and showed very minimal risks to patient safety. But the recent concerns over DES have start-ups and corporations pushing harder for bioabsorbable stents.

The Guidant Legacy: An Interview with Ron Dollens

Guidant emerged as one of the important device companies, all but creating the interventional cardiology business and playing a major role in the evolution of cardiac rhythm management. One person stood behind all of these accomplishments and guided Guidant virtually to its end: Ron Dollens, who retired as CEO last year just before the sale of the company to Boston Scientific was made final. Dollens talks about his career at Eli Lilly and Guidant and about his-and Guidant's-final days.

Headlines Obscure Robust Year for Devices in 2006

Although big companies grabbed the headlines with problems, 2006 proved to be a strong year for the medical device industry and growth prospects look strong. Our selection of the device industry highlights of 2006 includes: Boston Scientific-Guidant deal: the winner may be Abbott; Device IPO market remains strong; Drug-eluting stent safety debate; Conflicts of interest: (physician relationships with companies); The bid for Biomet; VC Pendulum shifts towards medical devices; Kyphon bids for St. Francis; and Diagnostic imaging and in vitro diagnostics converge.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT035038

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel